Narcolepsy- Competitive Landscape, Pipeline and Market Analysis, 2017, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Narcolepsy. This report provides information on the therapeutic development based on Narcolepsy mechanism of action dealing with around 120+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. DM’s Report also assesses the Narcolepsy therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 28+ active companies involved in the therapeutic development of the products
DM’s “Narcolepsy – Market Insights, Epidemiology and Market Forecast-2023” Report provides an overview of the disease and global market size of the Narcolepsy for the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan. It also includes global historical and forecasted epidemiological data for the prevalent, diagnosed and treatable cases of Narcolepsy from 2013-2023.
Narcolepsy is a chronic neurological / brain disorder which involves poor control of sleep and wakefulness. Narcolepsy is classically a tetrad of symptoms including EDS, cataplexy, sleep paralysis, and hypnagogic hallucinations.
Narcolepsy affects approximately 200,000 Americans and 3 million people worldwide. Narcolepsy is not rare, but it is severely under-recognized and commonly misdiagnosed. Narcolepsy appears throughout the world but occurrence rates vary among populations. The occurrence rate of narcolepsy is remarkably lower in Israel and quite higher in Japan compared to the United States. In Europe, the occurrence rate is found to be higher in UK and Germany than other European countries.
PROVIGIL by Cephalon, Inc and XYREM by Jazz Pharmaceuticals is the top selling drug for Narcolepsy contributing to majority of the market share. Other drugs are also being used for the treatment of Narcolepsy as secondary indication, but do not have much impact on the overall market size. We have estimated that the worldwide Narcolepsy will increase at a CAGR of 8.48% during the forecast period 2013-2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Request for a Demo Report at: https://www.diligentmarket.com/request-sample-page.php?gturl=13444
Scope of this report: The report provides competitive pipeline landscape of Narcolepsy. The report provides the marketed drugs information including its sales, development activities and details of patent expiry. The report provides the insight of current and future market for Narcolepsy. The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information. Coverage of the Narcolepsy pipeline on the basis of target, MOA, route of administration, technology involved and molecule type. The report reviews key players involved in the therapeutics development for Narcolepsy and also provide company profiling. The report also gives the information of dormant pipeline projects. Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages and Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.
Business insights delivered by this report are:-
- Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
- Complete MOA intelligence and complete understanding over therapeutics development for Narcolepsy
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Narcolepsy pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Key Coverage and Benefits
The report will help in developing business strategies by understanding the trends shaping and driving the global Narcolepsy market.
Identifying prevalent patient populations as well as risk factors in the global Narcolepsy market will help to improve product design, pricing, and launch plans
To understand the current pipeline scenario of different companies so as to make the Research activity more robust and competitive.
To understand the future market competition in the global Narcolepsy market And Insightful review of the key market drivers and barriers
The report also covers the detailed global historical and forecasted Narcolepsy
Market covering United States, European Union 5 (EU5 – Germany, Spain, Italy, France
And United Kingdom) and Japan from 2013-2025
Essential Points Covered in Table of Contain
Executive Summary Snapshot
Collaborations & Deal Value Trends
Companies collaborations for future developments
List of Figures are
Companies Collaborations vs. Financial year, 2017
Number of Companies Collaborations, 2017
Collaborations and Upfront Deal Values (In million, $), 2017
Number of Products under Development, 2017
Number of Products under Development by Companies, 2017
Number of Products under Development by Indication, 2017
DiligentMarket is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end to end comprehensive solutions to improve their performance and in making long lasting decision for their businesses.
We advise leading decision makers on their critical issues and opportunities; Research & Development, Strategy Making, Commercial, Operations, Competitive Intelligence, Competitive Landscaping and Mergers & Acquisition across all the Pharma and Biotech industries and geographies. We serve our clients by delivering practical and enduring results, and equipping our clients to grow and lead.
The pharmaceuticals market is in its growth stage and we are uniquely positioned to successfully endeavor the dimensions of the fast growing market by providing cutting-edge market and pipeline information, to our clients.
Connect With us on:
+91-750 707 8687